Expression of the cancer stem cell markers CD44v6 and ABCG2 in tongue cancer: Effect of neoadjuvant chemotherapy on local recurrence

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1153-1162

  Yanamoto, Souichi ^a   Yamada, Shin Ichi ^a   Takahashi, Hidenori ^a   Naruse, Tomofumi ^a   Matsushita, Yuki ^a   Ikeda, Hisazumi ^a   Shiraishi, Takeshi ^a   Seki, Sachiko ^a   Fujita, Shuichi ^a   Ikeda, Tohru ^a   Asahina, Izumi ^a   Umeda, Masahiro ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

ABCG2; Cancer stem cell; CD44v6; Neoadjuvant chemotherapy; Tongue cancer

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; CD44V6 ANTIGEN; HERMES ANTIGEN; TUMOR PROTEIN;

ADJUVANT THERAPY; ADULT; AGED; BIOSYNTHESIS; CANCER STEM CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TONGUE NEOPLASMS; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TONGUE NEOPLASMS;

EID: 84894461387     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2289     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global Cancer Statistics 2011. CA Cancer J Clin 61: 69-90, 2011.
2. Warnakulasuriya S: Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 45: 309-316, 2009.
3. Rogers SN, Brown JS, Woolgar JA, et al: Survival following primary surgery for oral cancer. Oral Oncol 45: 201-211, 2009.
4. Brandwein-Gensler M, Teixeira MS, Lewis CM, et al: Oral squamous cell carcinoma. Histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29: 167-178, 2005.
5. Kernohan MD, Clark JR, Gao K, Ebrahimi A and Milross CG: Predicting the prognosis of oral squamous cell carcinoma after first recurrence. Arch Otolaryngol Head Neck Surg 136: 1235-1239, 2010.
6. Yanamoto S, Yamada S, Takahashi H, et al: Clinicopathological risk factors for local recurrence in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 41: 1195-1200, 2012.
7. Liao CT, Chang JTC, Wang HM, et al: Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 15: 915-922, 2008.
8. Ord RA, Kolokythas A and Reynolds MA: Surgical salvage for local and regional recurrence in oral cancer. J Oral Maxillofac Surg 64: 1409-1414, 2006.
9. Braakhuis BJM, Bloemena E, Leemans CR and Brakenhoff RH: Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 46: 485-491, 2010.
10. Partridge M, Li SR, Pateromichelakis S, et al: Detection of minimal residual cancer to investigate why oral tumors recur despiteseemingly adequate treatment. Clin Cancer Res 6: 2718-2725, 2000.
11. van Houten VMM, Leemans CR, Kummer JA, et al: Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 10: 3614-3620, 2004.
12. Bilde A, von Buchwald C, Dabelsteen E, Therkildsen MH and Dabelsteen S: Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 38: 72-78, 2009.
13. Yanamoto S, Yamada S, Takahashi H, et al: Predictors of locoregional recurrence in T1-2N0 tongue cancer patients. Pathol Oncol Res 19: 795-803, 2013.
14. Kim JJ and Tannock IF: Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5: 516-525, 2005.
15. Yoshikawa M, Tsuchihashi K, Ishimoto T, et al: xCT-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 73: 1855-1866, 2013.
16. Naor D, Sionov RV and Ish-Shalom D: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71: 241-319, 1997.
17. Nagano O, Okazaki S and Saya H: Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 32: 5191-5198, 2013.
18. Jijiwa M, Demir H, Gupta S, et al: CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 6: e24217, 2011.
19. Lee HJ, Eom DW, Kang GH, et al: Colorectal micropapillary carcinomas are associated with poor prognosis and enriched in markers of stem cells. Mod Pathol 26: 1123-1131, 2013.
20. Gaviraghi M, Tunici P, Valensin S, et al: Pancreatic cancer spheres are more than just aggregates of stem marker-positive cells. Biosci Rep 31: 45-55, 2011.
21. Mack B and Gires O: CD44s and CD44v6 expression in head and neck epithelia. PLoS One 3: e3360, 2008.
22. Zhou S, Schuetz JD, Bunting KD, et al: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 67: 1028-1034, 2001.
23. Zhang P, Zhang Y, Mao L, Zhang Z and Chen W: Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Lett 277: 227-234, 2009.
24. Yanamoto S, Kawasaki G, Yamada S, et al: Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral Oncol 47: 855-860, 2011.
25. Bryne M, Koppang HS, Lilleng R and Kjaerheim A: Malignancy grading of the deep invasive margins of oral squamous cell carcinoma has high prognostic value. J Pathol 166: 375-381, 1992.
26. Asakage T, Yokose T, Mukai K, et al: Tumor thickness predicts cervical metastasis in patients with stage I/II carcinoma of the tongue. Cancer 82: 1443-1448, 1998.
27. Kurokawa H, Yamashita Y, Takeda S, Zhang M, Fukuyama H and Takahashi T: Risk factors for late cervical lymph node metastases in patients with stage I or II carcinoma of the tongue. Head Neck 24: 731-736, 2002.
28. Lim SC, Zhang S, Ishii G, et al: Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10: 166-172, 2004.
29. Sparano A, Weinstein G, Chalian A, Yodul M and Weber R: Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg 131: 472-476, 2004.
30. Huang SH, Hwang D, Lockwood G, Goldstein DP and O'Sullivan B: Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity. A meta-analysis of reported studies. Cancer 115: 1489-1497, 2009.
31. Fan KH, Wang HM, Kang CJ, et al: Treatment results of postoperative radiotherapy on squamous cell carcinoma of the oral cavity: coexistence of multiple minor risk factors results in higher recurrence rates. Int J Radiat Oncol Biol Phys 77: 1024-1029, 2010.
32. Schneider PM, Baldus SE, Metzger R, et al: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer. Ann Surg 242: 684-692, 2005.
33. Bollschweiler E, Besch S, Drebber U, et al: Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer. Ann Surg Oncol 17: 3187-3194, 2010.
34. Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64: 98-104, 2009.
35. Hang D, Dong HC, Ning T, Dong B, Hou DL and Xu WG: Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus 25: 638-644, 2012.
36. Zhao H, Ren J, Zhuo X, Ye H, Zou J and Liu S: Prognostic significance of surviving and CD44v6 in laryngeal cancer surgical margins. J Cancer Res Clin Oncol 134: 1051-1058, 2008.
37. Dalerba P, Cho RW and Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 58: 267-284, 2007.
38. Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768, 2008.
39. Graziano A, d'Aquino R, Tirino V, Desiderio V, Rossi A and Pirozzi G: The stem cell hypothesis in head and neck cancer. J Cell Biochem 103: 408-412, 2008.
40. Prince ME and Ailles LE: Cancer stem cells in head and neck squamous cell cancer. J Clin Oncol 26: 2871-2875, 2008.
41. Sinha N, Mukhopadhyay S, Das DN, Panda PK and Bhutia SK: Relevance of cancer initiating/stem cells in carcinogenesis and therapy resistance in oral cancer. Oral Oncol 49: 854-862, 2013.
42. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992.
43. Goodison S, Urquidi V and Tarin D: CD44 cell adhesion molecules. Mol Pathol 52: 189-196, 1999.
44. Wang SJ, Wong G, de Heer AM, Xia W and Bourguignon LY: CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 119: 1518-1530, 2009.
45. Yang YM and Chang JW: Bladder cancer initiating cells (BCICs) are among (initiating) cells. Cancer Invest 26: 725-733, 2008.
46. Shi J, Zhou Z, Di W and Li N: Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13: 182, 2013.
47. Shen B, Dong P, Li D and Gao S: Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med 2: 1151-1157, 2011.
48. Lore JM, Diaz-Ordaz E, Spaulding M, et al: Improved survival with preoperative chemotherapy followed by tumor response for advanced squamous cell carcinoma of the head and neck. Am J Surg 170: 506-511, 1995.
49. Pignon JP, Bourhis J, Domenge C and Designe L: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. Lancet 355: 949-955, 2000.
50. Licitra L, Grandi C, Guzzo M, et al: Primary chemotherapy in resectable oral cavity squamous cell carcinoma: a randomized controlled trial. J Clin Oncol 21: 327-333, 2003.
51. Olasz L, Szalma J, Orsi E, Tornoczky T, Marko T and Nyarady Z: Neoadjuvant chemotherapy: does it have benefits for surgeon in the treatment of advanced squamous cell cancer of the oral cavity? Pathol Oncol Res 16: 207-212, 2010.
52. Costa S, Terzano P, Bovicelli A, et al: CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 80: 67-73, 2001.
53. Saigusa S, Tanaka K, Toiyama Y, et al: Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemotherapy. Clin Oncol 23: 323-332, 2011.
54. Kawamoto A, Tanaka K, Saigusa S, et al: Clinical significance of radiation-induced CD133 expression in residual rectal cancer cells after chemoradiotherapy. Exp Ther Med 3: 403-409, 2012.
55. Sprenger T, Conradi L, Beissbarth T, et al: Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. Cancer 119: 26-35, 2013.